Androisoxazole
Androisoxazole (brand names Androxan, Neo-Ponden, Neo-Pondus), also known as 17α-methyl-5α-androstano[3,2-c]isoxazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT) that is marketed in Spain and Italy.[1][2][3][4] It is closely related to stanozolol, differing only in having an isoxazole instead of pyrazole ring fused to the A ring,[4] and is also related to furazabol, prostanozol, and danazol.
![]() | |
Clinical data | |
---|---|
Trade names | Androxan, Neo-Ponden, Neo-Pondus |
Other names | 17α-Methyl-5α-androstano[3,2-c]isoxazol-17β-ol |
Routes of administration | By mouth |
Drug class | Androgen; Anabolic steroid |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H31NO2 |
Molar mass | 329.484 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
References
- Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN 978-3-88763-075-1.
- Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 384–. ISBN 978-3-642-66353-6.
- ANTONINI FM, VERDI G (October 1961). "[Preliminary results of experience with a new anabolic steroid, "androisoxazole," in the aged.]". Minerva Medica (in Italian). 52: 3437–41. PMID 13861810.
- ARNOLD A, POTTS GO, BEYLER AL (December 1963). "RELATIVE ORAL ANABOLIC TO ANDROGENIC ACTIVITY RATIOS OF ANDROISOXAZOLE, ETHYLESTRENOL, METHYLANDROSTENOLISOXAZOLE AND TESTOSTERONE". Acta Endocrinologica. 44: 490–8. PMID 14082537.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.